Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Apr 15, 2010

Premium

Silence Therapeutics said it has named Max Herrmann as its new CFO.

Herrmann was most recently CFO of Intercytex, a public company focused on regenerative medicine. Before that, he spent 10 years as a sell-side equity analyst, most recently at ING. He also previously served as financial controller for Onyx Pharmaceuticals.

He holds a degree in microbiology from the University of Kent.


Biotech firm Taligen Therapeutics said that it has appointed Alnylam Pharmaceuticals CEO John Maraganore to its board of directors.

Before taking the helm of Alnylam, Maraganore was senior vice president of product development at Millennium Pharmaceuticals. He has also held roles at Biogen (now Biogen Idec) and Angiomax.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.